Search research articles
Contact Us
Filters
Showing results (71-80 of 173) with videos related to
Page
of 18
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 3, 2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
Ramez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, et al.
Gynecologic Oncology
|
April 29, 2025
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial
Andrés Poveda, Stéphanie Lheureux, Nicoletta Colombo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2023
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Ursula A Matulonis, Domenica Lorusso, Ana Oaknin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2023
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Funda Meric-Bernstam, Vicky Makker, Ana Oaknin, et al.
Gynecologic Oncology
|
October 26, 2024
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary
Kathleen N Moore, Domenica Lorusso, Ana Oaknin, et al.
Journal for Immunotherapy of Cancer
|
July 2, 2024
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer
Juan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, et al.
Gynecologic Oncology
|
September 15, 2021
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Stephanie Gaillard, Ana Oaknin, Isabelle Ray-Coquard, et al.
JAMA Oncology
|
July 25, 2024
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial
Michael Birrer, Guiling Li, Mayu Yunokawa, et al.
Gynecologic Oncology
|
October 15, 2023
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
Sileny N Han, Amit Oza, Nicoletta Colombo, et al.
British Journal of Clinical Pharmacology
|
November 9, 2024
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY
Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, et al.
Page
of 18
Search research articles
Search
Showing results (71-80 of 173) with videos related to
Sort By:
Page
of 18
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 3, 2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
Ramez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, et al.
Gynecologic Oncology
|
April 29, 2025
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial
Andrés Poveda, Stéphanie Lheureux, Nicoletta Colombo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 30, 2023
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Ursula A Matulonis, Domenica Lorusso, Ana Oaknin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2023
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Funda Meric-Bernstam, Vicky Makker, Ana Oaknin, et al.
Gynecologic Oncology
|
October 26, 2024
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary
Kathleen N Moore, Domenica Lorusso, Ana Oaknin, et al.
Journal for Immunotherapy of Cancer
|
July 2, 2024
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer
Juan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, et al.
Gynecologic Oncology
|
September 15, 2021
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Stephanie Gaillard, Ana Oaknin, Isabelle Ray-Coquard, et al.
JAMA Oncology
|
July 25, 2024
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial
Michael Birrer, Guiling Li, Mayu Yunokawa, et al.
Gynecologic Oncology
|
October 15, 2023
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
Sileny N Han, Amit Oza, Nicoletta Colombo, et al.
British Journal of Clinical Pharmacology
|
November 9, 2024
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY
Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, et al.
Page
of 18